Search Results - "Mangan, P. A."

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma by Olin, R L, Vogl, D T, Porter, D L, Luger, S M, Schuster, S J, Tsai, D E, Siegel, D L, Cook, R J, Mangan, P A, Cunningham, K, Stadtmauer, E A

“…Therapeutic options for patients with multiple myeloma whose disease has relapsed after a prior auto-SCT include novel biologic therapies, traditional…”
Get full text

Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen by Nazha, A, Cook, R, Vogl, D T, Mangan, P A, Gardler, M, Hummel, K, Cunningham, K, Luger, S M, Porter, D L, Schuster, S, O'Doherty, U, Siegel, D, Stadtmauer, E A

“…Lenalidomide is an active treatment for multiple myeloma (MM) and is increasingly used as part of the initial treatment of this disease. Recent reports have…”
Get full text

Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease by COHEN, A. D, LUGER, S. M, SICKLES, C, MANGAN, P. A, PORTER, D. L, SCHUSTER, S. J, TSAI, D. E, NASTA, S, GEWIRTZ, A. M, STADTMAUER, E. A

“…Gemtuzumab ozogamicin (GO) (Mylotarg, CMA-676) is a novel chemotherapeutic agent consisting of an anti-CD33 monoclonal antibody linked to calicheamicin, and is…”
Get full text

Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma by ANDREADIS, C, SCHUSTER, S. J, DOWNS, L. H, MANGAN, P. A, CUNNINGHAM, K. A, HUMMEL, K. A, GIMOTTY, P. A, SIEGEL, D. L, GLATSTEIN, E, STADTMAUER, E. A, CHONG, E. A, SVOBODA, J, LUGER, S. M, PORTER, D. L, TSAI, D. E, NASTA, S. D, ELSTROM, R. L, GOLDSTEIN, S. C

“…Although follicular lymphoma (FL) is generally responsive to conventional-dose chemotherapy, improved survival in patients with this disease has been difficult…”
Get full text

Partitioning 3D surface meshes using watershed segmentation by Mangan, A.P., Whitaker, R.T.

“…This paper describes a method for partitioning 3D surface meshes into useful segments. The proposed method generalizes morphological watersheds, an image…”
Get full text

Autologous stem-cell transplant after conventional dose adjuvant chemotherapy for high-risk breast cancer: Impact on the delivery of local-regional radiation therapy by Moore, H. C. F., Mick, R., Solin, L. J., Sickles, C., Mangan, P. A., Luger, S. M., Fox, K. R., Schuchter, L. M., Loh, E., Porter, D. L., Schuster, S., Buzby, G. P., Glatstein, E., Silberstein, L. E., Stadtmauer, E. A.

“…Background: High-dose chemotherapy with autologous stem-cell transplantation is used increasingly in the treatment of poor-prognosis primary breast cancer…”
Get full text

Stem cell transplantation for metastatic breast cancer : analysis of tumor contamination by STADTMAUER, E. A, TSAI, D. E, MAGEE, D. A, SACHS, R. A, WALL, M. E, MOORE, J, BUZBY, G. P, ZALETA, E, KAMOUN, M, SILBERSTEIN, L. E, SICKLES, C. J, MICK, R, LUGER, T. M, PORTER, D. L, MANGAN, P. A, SCHUCHTER, L. M, SCHUSTER, S. J, LOH, E. Y

“…The purpose of this study was to determine the efficacy, engraftment kinetics, effect of bone marrow tumor contamination, and safety of high-dose therapy and…”
Get full text

Cycles of Dose-Intensive Chemotherapy with Peripheral Stem Cell Support in Persistent or Recurrent Platinum-Sensitive Ovarian Cancer by Morgan, Mark A., Stadtmauer, Edward A., Luger, Selina M., Porter, David L., Mangan, Patricia A., O'neil, Patricia, Kamelle, Scott, Benjamin, Ivor, Mick, Rosemarie, King, Stephanie A., Rubin, Stephen C.

“…Objective.The objective was to determine the toxicity and surgically documented response rate of sequential high-dose chemotherapy with peripheral stem cell…”
Get full text

Lenalidomide and stem cell collection in patients with multiple myeloma by Cook, R. J., Vogl, D., Mangan, P. A., Cunningham, K., Luger, S., Porter, D. L., Tsai, D. E., Raguza-Lopez, M., Wiley, K., Masters, K., Stadtmauer, E. A.

“…Abstract only…”
Get full text

Outpatient autologous stem cell transplants for selected patients with myeloma: Morbidity, mortality, and duration of hospitalization by Liu, S., Vogl, D. T., Chong, E. A., Luger, S. M., Porter, D. L., Schuster, S. J., Tsai, D. E., Andreadis, C., Nasta, S. D., Mangan, P. A., Stadtmauer, E. A.

“…Abstract only 7104 Background: High-dose melphalan with autologous stem cell support improves survival for patients with myeloma but often requires prolonged…”
Get full text

A cohort study of desired services and barriers to service access among informal caregivers of patients with advanced cancer by Ingham, J. M., Cullen, J., Ogdie, A. R., Mangan, P. A., Taylor, K. L.

“…Abstract only…”
Get full text

A cohort study of desired services and barriers to service access among informal caregivers of patients with advanced cancer by Ingham, J. M., Cullen, J., Ogdie, A. R., Mangan, P. A., Taylor, K. L.

“…Abstract only…”
Get full text

A030 Long-Term Care Guidelines for Myeloma Patients by Moran, D, Bilotti, E, Rome, S, Richards, T, Faiman, BM, Colson, K, Westphal, J, Tariman, J, Spong, JE, Miller, K, Miceli, T, McCullagh, E, Mangan, PA, Love, G, Lilleby, K, Jenkins, BS, Doss, D, Daily, K, Bertolotti, P

Get full text